Nomex (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nomex, is an alpha‑adrenergic agonist presented as a nasal spray for nasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis by constricting blood vessels in the nasal mucosa. GNH USA supplies Nomex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride acts as a topical nasal decongestant to reduce swelling of the nasal passages. - Nasal congestion due to common cold: provides rapid relief of blocked nose and improves breathing. - Sinusitis‑associated congestion: decreases mucosal edema, facilitating sinus drainage. - Allergic rhinitis: alleviates nasal blockage caused by allergic inflammation.

Adverse reactions may occur with any nasal decongestant.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing or mild nosebleeds - Headache - Altered taste or bitter taste - Transient dizziness

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Cardiac arrhythmias - Nasal ulceration or perforation with prolonged use - Allergic reactions such as rash, itching, or swelling - Anaphylaxis (rare but life‑threatening) - Persistent nasal congestion beyond recommended duration (rebound congestion).

Use Nomex according to professional guidance and observe safety considerations. - Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Age restriction: avoid in children under 6 years unless directed by a healthcare professional. - Cardiovascular caution: patients with uncontrolled hypertension should use only under medical supervision. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Drug interactions: avoid concurrent use with other nasal decongestants or systemic sympathomimetics. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other agents that affect vascular tone or blood pressure.

Major Interactions (Avoid): - Other nasal decongestants (e.g., phenylephrine, oxymetazoline): risk of excessive vasoconstriction and hypertension. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive crisis when combined with sympathomimetic activity. - Tricyclic antidepressants: additive cardiovascular stimulation may raise blood pressure.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: nasal decongestant may counteract blood‑pressure‑lowering effects. - Beta‑blockers: may mask tachycardia signs of systemic absorption. - Selective serotonin reuptake inhibitors (SSRIs): monitor for possible increase in blood pressure.